<DOC>
	<DOCNO>NCT00134264</DOCNO>
	<brief_summary>The Torcetrapib project terminate December 2 , 2006 due safety finding . To demonstrate torcetrapib/atorvastatin reduce risk major cardiovascular disease event , compare atorvastatin alone , patient coronary heart disease risk equivalent</brief_summary>
	<brief_title>A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<criteria>Diagnosis coronary heart disease risk equivalent place patient high risk cardiovascular disease event Women pregnant lactating , plan become pregnant . Subjects clinically indicate need statin ( HMGCoA reductase inhibitor ) therapy atorvastatin concomitant therapy know lipid alter effect LDLC HDLC include fibrates nicotinic acid Subjects take drug know associate increase risk myositis combination HMGCoA reductase inhibitor Subjects medical condition laboratory abnormality could affect subject safety , preclude evaluationof response , render unlikely subject would complete study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>